A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Ross, MD
Infinity Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
28 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cancer Care Manitoba
Winnipeg, Manitoba, Canada
- Toronto Sunnybrook Regional Cancer Centre
Toronto, Ontario, Canada
- Jewish General Hospital
Montreal, Quebec, Canada
- Arizona Clinical Research Center
Tucson, Arizona, United States
- University of California San Diego Medical Center
San Diego, California, United States
- University of California San Francisco
San Francisco, California, United States
- Kaiser Permanente
Vallejo, California, United States
- University of Colorado Cancer Center
Aurora, Colorado, United States
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
- Kansas City Cancer Center
Overland Park, Kansas, United States
- Norton Health Care
Louisville, Kentucky, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- West Michigan Cancer Center
Kalamazoo, Michigan, United States
- Hackensack University Medical Center
Hackensack, New Jersey, United States
- Columbia University Medical Center
New York, New York, United States
- Weill Cornell Medical Center
New York, New York, United States
- University of Rochester
Rochester, New York, United States
- Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States
- Providence Portland Medical Center
Portland, Oregon, United States
- University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
- Rhode Island Hospital
Providence, Rhode Island, United States
- Institute of Translational Oncology Research
Greenville, South Carolina, United States
- Texas Oncology- Bedford
Bedford, Texas, United States
- Texas Oncology, Pa
Dallas, Texas, United States
- South Texas Oncology and Hematology
San Antonio, Texas, United States
- Tyler Cancer Center
Tyler, Texas, United States
- Virginia Oncology Associates
Newport News, Virginia, United States
- Seattle Cancer Care Alliance
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2010
- Primary completion
- 31 May 2012
- Completion
- 31 May 2012
- Last update posted
- 6 Mar 2017
- Registered enrollment
- 122
- Registry id
- NCT01130142
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.